For instance, even though T-DM1 failed to show clinical benefits in ToGA study-based HER2-positive gastric cancer compared with taxane, it seemed that HER2 expression was a predictive biomarker for T-DM1 against gastric cancer [16]. Here, ERBB2 is linked to gastric cancer.